Clinical Trials Logo

Clinical Trial Summary

The Metabolic Syndrome is a high prevalence disease worldwide. About a quarter of the adult population suffers the disease.

Resveratrol is a substance found in many plants, including grapes, nuts and wine, but it's also found in Polygonum cuspidatum. There is evidence that resveratrol consumption has beneficial effects on glucose and lipids metabolism, blood pressure and body weight.

The aim of this study was to evaluate the effect of resveratrol on metabolic syndrome, insulin sensitivity and insulin secretion.

The investigators hypothesis was that the administration of resveratrol modifies the metabolic syndrome, insulin sensitivity and insulin secretion.


Clinical Trial Description

A randomized, double-blind, placebo-controlled clinical trial was carried out in 24 patients with a diagnosis of metabolic syndrome in accordance with the International Diabetes Federation (IDF). Waist circumference, glucose, insulin levels, lipid profile, creatinine and acid uric were evaluated after a 75 g of dextrose load.

12 received resveratrol, 500 mg, three times per day (1500 mg) before meals during 3 months.

The remaining 12 patients received placebo with the same prescription.

Area Under the Curve of glucose and insulin was calculated as well as total insulin secretion (insulinogenic index), first-phase of insulin secretion (Stumvoll index) and insulin sensitivity (Matsuda index).

This protocol was approved by a local ethics committee and written informed consent was obtained from all volunteers.

Results are presented as mean and standard deviation. Intra and inter group differences were tested using the Wilcoxon signed-rank and Mann-Whitney U-test respectively; p≤0.05 was considered significant. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02114892
Study type Interventional
Source University of Guadalajara
Contact
Status Completed
Phase Phase 2
Start date April 2012
Completion date September 2013

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02702375 - Meta-analyses of Impotrant Food Sources of Sugars and Incident Cardiometabolic Diseases N/A
Completed NCT02649348 - Effects of Prehabilitation in Gastric Cancer Patients With Metabolic Syndrome on Perioperative Outcome N/A
Completed NCT02918422 - Controlled Clinical Study to Determine Novel Health Benefits of Cheese Consumption N/A
Completed NCT02356952 - Effect of a Low Glycemic Index on Metabolic Syndrome N/A
Completed NCT02459691 - Culturally-adapted Diabetes Prevention Lifestyle Intervention for Latinos (E-LITE Latinos) N/A
Completed NCT02337933 - Effect of Ursolic Acid Administration on Insulin Sensitivity and Metabolic Syndrome Phase 2
Completed NCT02402985 - Comparison of a Plant Protein Diet to a Animal Protein Diet Emphasized in Type 2 Diabetics N/A
Completed NCT01694056 - Soy Protein Intake and the Metabolic Syndrome N/A
Completed NCT00344903 - Dallas Heart Study 2: Return Clinic Visit for the Dallas Heart Study Cohort N/A
Recruiting NCT00408824 - Investigation of Genetic Risk of Metabolic Syndrome in Company Employee (NGK Study) N/A
Completed NCT00362908 - Effects of Low and Moderate Fat Diets on Lipids, Inflammation and Vascular Reactivity in the Metabolic Syndrome N/A
Completed NCT00395486 - ROMEO (Rosuvastatin in Metabolic syndrOme) Phase 4
Completed NCT00140816 - Dairy Products and Metabolic Effects (Norwegian Part) N/A
Completed NCT00455325 - Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS) Phase 2
Completed NCT00166036 - Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells Phase 2
Completed NCT00101517 - Partnership Programs to Reduce Ethnic Differences in the Risk of Cardiovascular Disease N/A
Recruiting NCT00177892 - Obstructive Sleep Apnea (OSA) and Metabolic Syndrome: Role of Oxidative Stress N/A
Completed NCT00074451 - Genomewide Search for Loci Underlying Metabolic Syndrome
Completed NCT00073775 - Epidemiology of Stress and the Metabolic Syndrome N/A
Completed NCT00200993 - Peripheral Effects of Exercise on Cardiovascular Health (STRRIDE I) Phase 2